Results 1 to 10 of about 7,229 (203)
Evaluation of drug-drug interaction between rilpivirine and rifapentine using PBPK modelling [PDF]
Frontiers in Pharmacology, 2022 Tuberculosis remains the leading cause of death among people living with HIV. Rifapentine is increasingly used to treat active disease or prevent reactivation, in both cases given either as weekly or daily therapy.
Sandra Grañana-Castillo +4 more
doaj +2 more sources
Rilpivirine inhibits SARS-CoV-2 protein targets: A potential multi-target drug
Journal of Infection and Public Health, 2021 Background: COVID-19 disease caused by SARS-CoV-2 is lacking efficient medication although certain medications are used to relief its symptoms. Objectives: We tested an FDA-approved antiviral medication namely rilpivirine to find a drug against SARS-CoV ...
Rakesh Davella +2 more
exaly +3 more sources
The development of an effective synthetic route of rilpivirine [PDF]
BMC Chemistry, 2021 Background Rilpivirine (RPV) was approved by the U.S. FDA (Food and Drug Administration) in 2011 to treat individuals infected with human immunodeficiency virus 1 (HIV-1). Significantly, rilpivirine is three fold more potent than etravirine.
Tao Zhang +7 more
doaj +4 more sources
The role of rilpivirine in Southern Africa
Southern African Journal of HIV Medicine, 2019 Rilpivirine, a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), is included as an option in first-line antiretroviral therapy (ART) for antiretroviral-naïve individuals in treatment guidelines in high-income countries, including ...
Michelle A. Moorhouse, Karen Cohen
doaj +5 more sources
On the Verge of the 3000th Publication: Reflections on Deceptions, Successes and Perspectives [PDF]
MoleculesA lifelong career devoted to the development of specific antiviral agents eventually yielded, besides (almost) 3000 publications, about ten antiviral compounds that were approved and marketed as antiviral drugs, i.e., DHPA (Duviragel®), BVDU (Zostex ...
Erik De Clercq
doaj +2 more sources
Patient-Reported Outcomes with Long-Acting Cabotegravir and Rilpivirine in People Living with HIV [PDF]
Patient Preference and AdherenceAna Codonal,1,2 Alicia Lázaro,2,3,* Elena Martínez,4,* Alberto Delgado,4,* Miguel Torralba2,4,5,*1Pharmacy Department, Santos Reyes Hospital, Aranda de Duero, Spain; 2University of Alcalá, Alcalá de Henares, Spain ...
Codonal A +4 more
doaj +2 more sources
Journal of Pharmaceutical Research, 2022 A simple, sensitive, specific, accurate, and stability-indicating reversed phase high performance liquid chromatographic method was developed for the simultaneous determination of cabotegravir and rilpivirine in injection dosage form, using a ...
A Suneetha +3 more
doaj +1 more source
Real-life efficacy and satisfaction of long-acting ART Cabotegravir-Rilpivirine in HIV-infected individuals [PDF]
Infectious Diseases and Tropical Medicine, 2023 OBJECTIVE: Switching from oral anti-retroviral therapy (ART) to intramuscular administration of Cabotegravir-Rilpivirine (CAB+RPV) has been observed to decrease the number of pills that patients need to take, enhance patient satisfaction, and promote ...
S. Spampinato +8 more
doaj +1 more source
Frontiers in Pharmacology, 2021 Objectives: To investigate the safety and pharmacokinetic profiles of long-acting injectable pre-exposure prophylaxis (LAI PrEP), notably cabotegravir (CAB-LA) and rilpivirine (RPV-LA), for the prevention of human immunodeficiency virus-1 (HIV-1 ...
Gilbert Lazarus +7 more
doaj +1 more source
Pharmaceutics, 2022 SHCS#879 is an ongoing Switzerland-wide multicenter observational study conducted within the Swiss HIV Cohort Study (SHCS) for the prospective follow-up of people living with HIV (PLWH) receiving long-acting injectable cabotegravir-rilpivirine (LAI-CAB ...
Paul Thoueille +20 more
doaj +1 more source